LFCR.O PE Ratio & Valuation, Is LFCR.O Overvalued

Historical Valuation

Lifecore Biomedical Inc (LFCR.O) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.17 is considered Undervalued compared with the five-year average of -80.68. The fair price of Lifecore Biomedical Inc (LFCR.O) is between 8.88 to 11.48 according to relative valuation method. Compared to the current price of 4.72 USD , Lifecore Biomedical Inc By Undervalued By 46.86%.

Relative Value

Fair Zone

8.88-11.48

Current Price：4.72

46.86%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lifecore Biomedical Inc (LFCR.O) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lifecore Biomedical Inc (LFCR.O) has a current Price-to-Book (P/B) ratio of 4.52. Compared to its 3-year average P/B ratio of 47.48, the current P/B ratio is approximately -90.48% higher. Relative to its 5-year average P/B ratio of 29.32, the current P/B ratio is about -84.58% higher. Lifecore Biomedical Inc (LFCR.O) has a Forward Free Cash Flow (FCF) yield of approximately 1.71%. Compared to its 3-year average FCF yield of -10.53%, the current FCF yield is approximately -116.19% lower. Relative to its 5-year average FCF yield of -12.22%, the current FCF yield is about -113.96% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LFCR competitors is 5.03, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR.O) exhibits a P/S ratio of --, which is NaN% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LFCR.O increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LFCR.O in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LFCR.O currently overvalued or undervalued?

Lifecore Biomedical Inc (LFCR.O) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.17 is considered Undervalued compared with the five-year average of -80.68. The fair price of Lifecore Biomedical Inc (LFCR.O) is between 8.88 to 11.48 according to relative valuation method. Compared to the current price of 4.72 USD, Lifecore Biomedical Inc is Undervalued By 46.86%.

What is Lifecore Biomedical Inc (LFCR.O) fair value?

LFCR.O's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lifecore Biomedical Inc (LFCR.O) is between 8.88 to 11.48 according to relative valuation method.

How does LFCR.O's valuation metrics compare to the industry average?

The average P/S ratio for LFCR.O's competitors is 5.03, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR.O) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for Lifecore Biomedical Inc (LFCR.O) as of Apr 10 2026?

As of Apr 10 2026, Lifecore Biomedical Inc (LFCR.O) has a P/B ratio of 4.52. This indicates that the market values LFCR.O at 4.52 times its book value.

What is the current FCF Yield for Lifecore Biomedical Inc (LFCR.O) as of Apr 10 2026?

As of Apr 10 2026, Lifecore Biomedical Inc (LFCR.O) has a FCF Yield of 1.71%. This means that for every dollar of Lifecore Biomedical Inc's market capitalization, the company generates 1.71 cents in free cash flow.

What is the current Forward P/E ratio for Lifecore Biomedical Inc (LFCR.O) as of Apr 10 2026?

As of Apr 10 2026, Lifecore Biomedical Inc (LFCR.O) has a Forward P/E ratio of 8.67. This means the market is willing to pay $8.67 for every dollar of Lifecore Biomedical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lifecore Biomedical Inc (LFCR.O) as of Apr 10 2026?

As of Apr 10 2026, Lifecore Biomedical Inc (LFCR.O) has a Forward P/S ratio of 1.17. This means the market is valuing LFCR.O at $1.17 for every dollar of expected revenue over the next 12 months.

LFCR.O Valuation